2 tracked superinvestors hold Bio-Rad Laboratories, Inc. (BIO), worth $598M combined, led by First Eagle. Smart money is holding BIO as of the latest 13F filings.
Current price
$386.11
+33.4%
1Y
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible…
Market cap
$6.9B
P/E
42.76
Div yield
0.0%
Revenue YoY
0.7%
Analyst target
$350
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
2
tracked 13F / N-PORT funds
Combined value
$598M
disclosed long exposure
Tier-1 conviction
0
concentrated holders
Net this quarter
0
0 buying · 0 selling
Smart money is holding BIO steady this quarter — buys and sells are balanced.
Bio-Rad Laboratories, Inc. (BIO) appears mainly in diversified and quant books here (2 funds, $598M combined) rather than in concentrated conviction portfolios — read the holders below with that in mind.
The largest position belongs to First Eagle at 0.8% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
Tracked holders were largely static this quarter — no new opens, adds or trims of size — suggesting the position is being held rather than actively traded.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Held | 0.8% | $526M | |
| Held | 1% | $72M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Which superinvestors own BIO?
2 tracked funds hold Bio-Rad Laboratories, Inc. (BIO), the largest being First Eagle (First Eagle Global) at 0.8% of its 13F portfolio. 0 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling BIO?
In the most recent 13F quarter, 0 tracked funds added or opened BIO and 0 trimmed it.
How much BIO do tracked funds hold?
Combined disclosed long exposure to BIO across tracked superinvestors is $598M as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.